http://www.masshightech.com/latestnews.html Mass High Tech: The Journal of New England Technology : breaking news from Mass High Tech Tue, 24 Nov 2009 18:29:05 -0500 en-US http://www.masshightech.com/ http://www.masshightech.com/images/flag.gif http://www.masshightech.com/stories/2009/11/23/daily19-Shire-files-for-EU-drug-approval.html Tue, 24 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology Shire plc has submitted an application for approval to European regulators for its drug target, velaglucerase alfa. The drug candidate, for Gaucher disease, is an alternative to Genzyme Corp.’s Cerezyme. Regulators in both the U.S. and Canada have already fast-tracked the drug to help head off a shortage of Cerezyme, due to the temporary closure of a Genzyme plant in Allston. http://www.masshightech.com/stories/2009/11/23/daily18-NIH-awards-stimulus-funds-to-Marine-Biological-Laboratory.html Tue, 24 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology The Marine Biological Laboratory reports it has landed more than $800,000 in federal stimulus funds from the National Institutes of Health to recruit researchers specializing in regenerative biology. http://www.masshightech.com/stories/2009/11/23/daily17-FDA-delays-CombinatoRx-drug-decision.html Tue, 24 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology The U.S. Food and Drug Administration has advised Cambridge-based CombinatoRx Inc. (NASDAQ: CRXX) and Canada-based Neuromed Pharmaceuticals Inc.,that the agency will put off making a decision on whether to approve the companies’ pain drug target for three months. http://www.masshightech.com/stories/2009/11/23/daily14-BK-Medical-signs-distribution-deal-with-MedAssets.html Tue, 24 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology Ultrasound technology developer BK Medical has struck a distribution deal with MedAssets Supply Chain Systems to make BK’s urological and surgical ultrasound products available to health care providers in its network. http://www.masshightech.com/stories/2009/11/23/daily2-Millipore-buys-out-Indian-joint-venture.html Mon, 23 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology Millipore Corp. has bought full ownership of its joint venture in India, Millipore India Pvt. Ltd., a business based in Bangalore that employs 300 people. Millipore (NYSE:MIL) had previously owned 40 percent of Millipore India. http://www.masshightech.com/stories/2009/11/23/daily1-Ironwood-looks-to-IPO-hopes-for-172M.html Mon, 23 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology Ironwood Pharmaceuticals Inc., a Cambridge-based maker of antibacterial drugs, has filed to go public, hoping to raise $172 million and trade on the Nasdaq. Ironwood, which was founded as Microbia in 1999, has raised a total of $306 million in financing to date. http://www.masshightech.com/stories/2009/11/16/daily61-Biogen-shareholders-CEO-pay-inconsistent-with-poor-stock-performance.html Fri, 20 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology One of Biogen Idec Inc.’s largest investors is criticizing CEO James Mullen’s compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance. http://www.masshightech.com/stories/2009/11/16/daily60-Corindus-raises-47M-in-equity-funds.html Fri, 20 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology Vascular robotic systems developer Corindus Inc. has pulled in $4.68 million of a planned $10 million equity financing. The Natick-based company designs, develops and markets remote control systems for cardiology operations. http://www.masshightech.com/stories/2009/11/16/daily53-CambridgeSofts-private-financing-worth-31M.html Fri, 20 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology CambridgeSoft Inc. has disclosed the dollar value of a private financing it announced earlier this week, reporting in a regulatory filing that the equity funding received from Health Evolution Partners and Goldman Sachs & Co. was worth $31.3 million. The value of the deal was previously undisclosed. http://www.masshightech.com/stories/2009/11/16/daily52-Second-license-deal-with-Amgen-to-bring-ImmunoGen-another-35M.html Fri, 20 Nov 2009 00:00:00 -0500 Mass High Tech: The Journal of New England Technology Waltham biotechnology firm ImmunoGen Inc. has announced a second license granted to Amgen Inc. for its maytansinoid Targeted Antibody Payload technology for an undisclosed target. The deal promises a $1 million upfront payment to ImmunoGen, with up to $34 million in milestone payments and additional royalties.